MedTrace Logo

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

NCT05465902 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-03-28

No results posted yet for this study

Summary

This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial.

The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral Vector COVID-19 vaccines (one or two doses) and have not been infected with COVID-19. All subjects will be evaluated for safety and immunogenicity after a single dose booster immunization with Recombinant COVID-19 variant Vaccine (Sf9 Cell) or inactivated COVID-19 vaccine (Vero cell) or mRNA vaccine or Viral Vector vaccine.

Conditions

Interventions

BIOLOGICAL

Recombinant COVID-19 variant Vaccine (Sf9 Cell)

1dose, Intramuscular Injection

BIOLOGICAL

COVID-19 Vaccine (Vero Cell), Inactivated

1dose, Intramuscular Injection

BIOLOGICAL

mRNA COVID-19 vaccine (Moderna)

1dose, Intramuscular Injection

BIOLOGICAL

Viral Vector COVID-19 vaccine (AstraZeneca)

1dose, Intramuscular Injection

Sponsors & Collaborators

  • WestVac Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-07
Primary Completion
2024-11-30
Completion
2024-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465902 on ClinicalTrials.gov